PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

• Autores principales: Kimiko Koiwai (Autor), Raouf El‐Cheikh (Autor), Hoai‐Thu Thai (Autor), Claire Brillac (Autor), Jean‐Baptiste Fau (Autor), Christine Veyrat‐Follet (Autor), Marie‐Laure Risse (Autor), Helgi van deVelde (Autor), Dorothée Semiond (Autor), Laurent Nguyen (Autor)
• Formato: Libro
• Publicado: Wiley, 2021-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refractory multiple myeloma (RRMM). The PK/PD m...